(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Showing 11 - 16 of 16 records.
This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....More
The purpose of this study is to find a recommended dose level of LY2940680 that can be safely given to children with medulloblastoma or rhabdomyosarcoma that has returned or doesn't respond to initial treatment. The study will also explore the changes in a cancer marker levels. Finally, the study w...More
This phase I trial
studies the side effects and best dose of azurin-derived cell-penetrating
peptide p28 (p28) in treating patients with recurrent or progressive central
nervous system tumors. Drugs used in chemotherapy, such as azurin-derived
cell-penetrating peptide p28, work in different way...More
This phase I/II trial studies the side effects
and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in
treating younger patients with solid tumors that have come back or that have
not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan
hydrochloride may stop the...More
This phase II trial studies how well
peginterferon alfa-2b works in treating younger patients with craniopharyngioma
that is recurrent or cannot be removed by surgery. Peginterferon alfa-2b may
interfere with the growth of tumor cells and slow the growth of
The objective of this study is to validate 3'-deoxy-3'-[F-18] fluorothymidine (18F-FLT) as a measure of tumor proliferation and to demonstrate the utility of 18F-FLT as a PET imaging agent in children with central nervous system tumors....More
Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at firstname.lastname@example.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.
The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center